Fundación MEDINA will participate in the European Project H2020 TOPCAPI, for the generation of microbial cell factories to produce advanced pharmaceutical ingredients. MEDINA will participate in developing the tools for the biotechnological production of a new anti-acne drug, in Phase II clinical trials, and three related drugs against multidrug resistant bacteria MRSA, in Phase III clinical trials.
For that purpose, two common microbial bacteria will be characterized using systems biology approaches, applying integrated data analysis to transcriptomics and metabolomics experiments, combined with predictive mathematical modelling to drive the rapid improvement of these microbial cell factories for industrial production of these drugs. At the same time, we will establish a toolbox for future engineering high value advanced pharmaceutical ingredients.
The 4-year Project will include: 1) Host engineer two new actinomycete strains, as carriers where to integrate genetic pathways for the production agents discovered in other microbes, 2) The introductions of the biosynthesis pathways to obtain the anti-acne and anti-multidrugresistent drugs, and 3) the optimization of the production of these pharmaceutical agents for a high efficiency and a low generation of impurities.
